The Most Expensive Item in the Women's Transfer Window Isn't the Fee — It's the Medical File

In January 2026 Chelsea announced the signing of Naomi Girma. The reported fee was around 1.1 million euros, widely described as the first seven-figure transfer in the history of women's football. I read the announcement three times. It is a habit: when a club makes noise about a big fee, I go looking for the word "medical". There was a name, a fee, a celebration. Not one line of medical detail. No clearance date, no fitness condition, no mention of the workload of the previous twelve months.

This is not a complaint against Chelsea. Pick up the announcements of the other big women's transfers in that same window and the language is nearly identical. Fifty years between the Salt Lake press box and the Manchester tribunes taught me one rule: the most expensive thing in football is the thing written about least.

In March 2026, when football stopped, I got six weeks in Didsbury staring at a wall — the first stretch of adult life with nothing to react to. Those six weeks taught me a slower way to watch. Since then I read transfer news in two layers: what is being told, and what is being kept from being told.

The women's market has scaled. Fees have crossed seven figures, wages have risen, broadcast deals have grown, stadiums fill. The men's game carries an entire rumour economy — tiers, reporter credibility, agent-motive checks, a reader who knows what weight to give each claim. Women's football got visibility without the same transparency. Which means the coverage in this window is concentrated on the fee, while the real risk sits in the medical record.

The risk is not theoretical. In July 2026, days before the European Championship, Alexia Putellas's knee went. November 2026, Beth Mead. December 2026, Vivianne Miedema. April 2026, Leah Williamson — weeks before the World Cup. Four of the biggest names in the sport, four ACLs, eighteen months. That is not a statistical coincidence; studies across the past decade have repeatedly put ACL incidence among women footballers several times higher than among men. The picture is public. The file behind the picture is not.

This is where the argument really begins. Clubs disclose injury when disclosure helps the balance sheet, and stay silent when it doesn't. A serious injury is announced when forty thousand people in a stadium are demanding to know why she isn't playing, or when ticket sales start to feel it. What gets published is a press release, not a clinical report. It carries no mechanism — only "knee injury". ACL, meniscus, cartilage: three different recovery curves, three different market values. The reader is never told which one.

The notebook remembers what the broadcast forgets. I have kept a simple ledger since 2026: which player played how many minutes in which month, and what happened in the six months after. Following the 2026 World Cup I cross-checked that ledger against the 2026 WSL season. The players who had gone through three competitions back to back in 2026-23 — league, domestic cup, European qualifiers, then national team — either lost minutes the following season or disappeared into a long break. That is a pattern, not a conclusion. But a pattern only exists if somebody records it. Nobody is recording it.

Now the economics, because that is my language. On the men's scale, that 1.1 million euros in January 2026 looks small. On the women's scale it is a record — and a record fee means the buying club has placed a large bet on an asset whose medical history is not public. In the men's market that asymmetry is partly absorbed by insurance, resale value and deep squads. In the women's game squads are thin, medical staffing is small, financial cushioning is limited. One ACL can reshape an entire club season, and nobody publicly prices that risk.

The consequence shows up in contract structure, which is where the real story hides. When injury information is opaque, clubs protect themselves through international-clearance clauses, appearance-linked payments and insurance-adjusted instalments. The reader sees the fee. The conditions, the risk-sharing, the payment schedule stay invisible. The media chases the one number that is easiest.

I connect this to my own experience, and I should be clear that my experience is Indian administration, not European. From July 2026 to March 2026 I was in the AIFF's communications department. What I learned there is that institutions do not hide information because they are lying — they hide it because there is no incentive structure for disclosure. What becomes public is what travels with the president's photograph. Injury information runs on exactly that logic: show what pleases the sponsor, bury what invites a doctor's testimony.

The player is the weakest link in that equation, and the part the media covers least. A recovery video gets made — dim light, treadmill, music, a caption reading "the comeback begins". That video is a club product, not a player statement. The comeback gets marketed. The comeback data does not.

And here is where I have to correct myself. First: I am a 68-year-old man writing from a Manchester desk about the injury economics of women's football. The easiest and most wrong frame available is that women's bodies are fragile. I reject that in plain terms. The research points at structure, not biology — fixture congestion, boot design not built around the female foot, thin medical staffing in domestic leagues, and a calendar with no off-season left in it. The risk is in the schedule, not the body.

Second: confidentiality is not a conspiracy. Medical privacy is the player's right and I respect it; data-protection law sits on the same side. My argument is not that everything should be public. My argument is about asymmetry: the information exists, and it sits with the people who trade on it rather than the people who rely on it. The agent gets the scan, the supporter gets the video. That is not medical confidentiality. That is a market imbalance.

Third: I should concede that the beat has moved past me. I don't get to the stadium daily any more. I call the people who do. In January a women's football reporter told me clubs tell journalists only what won't damage ticket sales — and that the most reliable source is always the players' own teammates, never the club statement. She was less polite about it than I am. She was right.

Which brings back the question I left the Kolkata press box with and which is still open: who pays, who benefits, and who is protected from competition? In this window the beneficiaries are the people holding the medical file. The payers are the people buying a shirt with a name on the back and an injury history nowhere on the front.

My prediction, with a date attached so no excuse survives: within the next three transfer windows — by the summer of 2026 — at least one top-tier women's transfer will be publicly restructured or cancelled on medical grounds, and that will be the first formal moment this market admits it prices injury. If it doesn't happen, we will keep doing what we have done for five years: watching the video, counting the fee, and assuming that what was never disclosed is not a risk.